Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: Board Chairman and CEO
Company: QIAGEN (Suzhou) Translational Medicine Co., Ltd
个人简介:
With 25 years of drug R&D experience and years of experience in translational science and diagnostics, Nick is now the board chairman and CEO for QIAGEN (Suzhou) Translational Medicine Co., Ltd, which is an integrated precision medicine diagnostic solution provider for biomarker, companion diagnostics development and clinical testing. Nick was China GM and Corporate SVP for Frontage Lab, and a founding director and executive for Novartis China R&D center. Before that, Nick was a director at US OSI Pharmaceuticals and a manager at Pfizer global R&D center.  Nick filed 6 INDs/IMPD and 1 NDA/MAA for various dosage forms. Nick represented Pfizer serving on the PRQI working committee (formed among FDA, industry and academia) and also represented Bayhelix serving on sFDA CMC working committee. Before going to US, Nick worked and studied at Chinese Academy of Sciences. And he got his Ph.D. degree from University of Cincinnati. Nick is now a member of Bayhelix, a global association of Chinese Life Science Business Executives; an invited vice president of Jiangsu Life Science and Technology Association; and a director of Biomedical Committee (SEBMC), Sino-EU Chemical/Manufacturer Association. He is one of 5 founders and deputy director for China Precision Medicine and Companion Diagnostics Consortium. Nick is the recipient of the China Suzhou SIP Leading Talent Award, China Jiangsu Province Entrepreneur and Innovation Talent Award, and China national One-Thousand-Plan Talent Expert Award.
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: CEO/President
Company: McCull Pharmaceutical / SUBIA-Sino-US Biomedical Investment Association
个人简介:
John is the president and chief executive officer of McCull Pharma, BlueStone BioScience, and the founding director at a number of startup biotech companies. John Niu is also a co-founder of BlueRock Venture and focuses on advances in biotech and drug innovation. Prior to the founding of McCull Pharmaceuticals, John worked with Sanofi-Aventis and Merck and held a variety of roles of increasing responsibility in pharmaceutical research and development. John also played a key role in leading SUBIA (Sino-US Biomedical Investment Association) for promoting innovation and capital investment cross the border of US and China. John received his Ph.D in Chemistry and Toxicology from Iowa State University in US.
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: CEO
Company: Genor Biopharma Co. Ltd, Walvax Bio Group
个人简介:
Dr. Zhou, Xinhua (Dr. Joe Zhou) is the Present and Chief Scientist of Genor Biopharma. He has been selected as a national expert of the TOP 1000 TALENTS program in China since 2010. Dr. Zhou also is a visiting professor teaching Master Degree Program in International Pharmaceutical Engineering Management (IPEM) at Peking University, China. He is an invited vice-chair of Biopharmaceuticals Committee under China Pharmaceuticals Society, the Founder and first Chair of China Protein Drug Quality Alliance (CPDQA), the Founder and first Chair of Biological Drug Product and Process Committee of China ISPE, and the Founder and first Chair of Amgen Aluminums Association (AAA) in China. Previously, Dr. Zhou was Scientific Director at Amgen for bioprocess development and trouble shooting for bioprocess and bio-manufacturing. He has over 20-years industrial experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, viral clearance, real time analytical assays, formulation and product specification for drug substances and drug products.
发布时间: 2019 - 07 - 10
点击次数: 0
Positions: Chief Strategy Officer
Company: Deuracor Therapeutics, Inc.
个人简介:
Dr. Bin Shi (石斌)joins a startup in August 2018 serving as VP and Chief Strategy Officer for Biology and Business Development functional areas. Previously, Bin worked for Amgen, serving as Head of External R&D and Licensing of Amgen Asia R&D Center (2016 - 2018) to leverage wide external scientific and technology expertise in China and Asian Pacific areas to advance and complement Amgen’s global internal effort in discovery of breakthrough medicines. Before that, Bin worked in Merck and Schering-Plough (1998-2016), overseeing anti-cancer, anti-viral, neuroscience, and vaccine drug discovery and development. Bin has published more than 40 papers, abstracts and patents in reputed journals including JBC, Cancer Research etc, serving as the first and corresponding author, serving as an invited reviewer for eight peer reviewed journals, editorial board member and an invited speaker and meeting chairman at several conferences. She is an invited Industry Mentor by ShanghaiTech Univ. and Nankai Univ. Bin is a lifetime SAPA member, and served as President (2016-2017) in SAPA-GP; a member of BayHelix; an active member of AACR. Bin completed her Ph.D. at Thomas Jefferson University in Philadelphia, her Master of Science degree at State University of New York (SUNY) in Syracuse, and her Bachelor of Science degree at Nankai University in Tianjin China.